Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis drug OTEZLA tested in everyday use

NCT ID NCT03284879

Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This completed study observed over 1,000 people with psoriasis who were prescribed OTEZLA (apremilast) for the first time. Researchers tracked side effects, symptom improvement, and quality of life over several years. The goal was to see how well the drug works in real-world settings, outside of a controlled clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Apremilast (OTEZLA)
What this could lead to
If successful, this study could confirm that OTEZLA is a safe and effective option for managing psoriasis in everyday medical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It also does not compare OTEZLA to other treatments or a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,086 people

The number who actually took part.

Started

Sep 2017

Finished

Mar 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who have received a diagnosis of either of the following diseases and have received OTEZLA for the first time will be included in this survey. * Psoriasis vulgaris that is with an inadequate response to topical therapies * Psoriasis arthropathica

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Patients who have received a diagnosis of either of the following diseases and have received OTEZLA for the first time will be included in this survey. * Psoriasis vulgaris that is with an inadequate response to topical therapies * Psoriasis arthropathica Exclusion Criteria: * N/A

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression digestive system disorder neoplasm psoriasis psoriatic arthritis Suicidal Ideation vasculitis Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Tugi dermatology clinic

    Kitakyushu, Fukuoka, 804-0081, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.